Table 2.
Toxicity | Protons: MGH (n = 10) Median f/u: 5 y |
IRS II-III (n = 213) Median f/u: 7 y |
IMRT: MSKCC† (n = 21) Median f/u: 2 y |
University of Iowa‡ (n = 17) Median f/u: 20 y |
||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Decreased growth velocity | 3/10 | 30 | 92/190 | 48 | NR | 9/15 | 60 | |
Growth hormone replacement | 2/10 | 20 | 36/190 | 19 | 1/21 | 5 | 6/15 | 40 |
Other endocrinopathies | 1/10 | 10 | 17/213 | 8 | NR | 1/15 | 7 | |
Facial hypoplasia | 7/10 | 70 | 74/76 | 97 | 1/21 | 5 | 11/15 | 73 |
Visual complications | 0 | 45/213 | 21 | 2/21 | 10 | 9/11 | 82 | |
Auditory complications | 0 | 36/213 | 17 | NR | 6/8 | 75 | ||
Dentition | 3/10 | 30 | NR | NR | 7/7 | 100 | ||
Chronic nasal and sinus congestion | 2/10 | 20 | 35/71 | 49 | 4/21 | 19 | NR | |
Secondary malignancies | 0 | 4/213 | 2 | 2/21 | 10 | 1/17 | 6 |